


FLUID

IMAGING DRUG DISCOVERY



WHO WE ARE

At FLUID, we combined over 15 years experience in rational drug design and MRI brain imaging to create a unique proprietary molecular imaging method. This novel method is capable of identifying small molecules localizing in the brain of small laboratory animals without the requirement of ionizing agents.

WHAT WE DO

By localizing clinical candidates after the initial scale-up synthesis and during the stability tests, value-adding information for the clinical candidates is obtained increasing the chance of success for the traditional ^{14}C or PET distribution studies. Costs associated with traditional distribution studies are thus significantly reduced, and the risk in selecting the correct clinical candidate is mitigated.

BENEFITS FOR EMPLOYING FLUID'S IMAGING DRUG DISCOVERY (ID'D) PROPRIETARY PLATFORM:

Molecular localization of cold compounds

- No requirement for specialized radioactive compound management, storage, equipment, permits, or skilled employees
- Imaging of molecules after scaled syntheses thus costs for brain localization already in functioning costs of scale-up and stability studies
- No alternative synthesis routes required to incorporate radio-labels in the clinical candidates
- Extended shelf life of the cold compounds
- Safe: the lack of non-ionizing agents signifies that even volatile compounds, such as anesthetics, can be studied safely

Non-invasive imaging modality without surgical procedures

- Animals can be reused or retested on short periods of time
- Fast and specific to the compound atomic composition
- Time courses of compound brain localization

Added value

- Proof in concept for new molecular type brain exposure
- Pre-filtering for clinical candidate selection
- Applicable for drug library design

Risk evaluation for imaging with ionizing agents

- More information = better decision
- Never randomly select compounds for radio-labeled distribution studies again!

